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The present study investigated the roles of E6 and E6AP in the Wnt pathway. We showed that E6 levels
are markedly reduced in cells in which Wnt signaling is activated. Coexpression of wild-type or mutant
E6AP (C820A) in Wnt-activated cells stabilized E6 and enhanced Wnt/β-catenin/TCF transcription.
Expression of E6AP alone in nonstimulated cells elevated β-catenin level, promoted its nuclear
accumulation, and activated β-catenin/TCF transcription. A knockdown of E6AP lowered β-catenin
levels. Coexpression with E6 intensiﬁed the activities of E6AP. Further experiments proved that E6AP/E6
stabilize β-catenin by protecting it from proteasomal degradation. This function was dependent on the
catalytic activity of E6AP, the kinase activity of GSK3β and the susceptibility of β-catenin to GSK3β
phosphorylation. Thus, this study identiﬁed E6AP as a novel regulator of the Wnt signaling pathway,
capable of cooperating with E6 in stimulating or augmenting Wnt/β-catenin signaling, thereby possibly
contributing to HPV carcinogenesis.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Infection of the anogenital mucosa with human papillomavirus
(HPV) types referred to as “high risk” or oncogenic, such as HPV16
and HPV18, is a major factor for the subsequent development of
cancer (DiMaio and Liao, 2006). Two oncoproteins, E6 and E7, are
encoded by the oncogenic HPVs. These proteins are consistently
expressed in HPV-positive cancers and contribute to the initial
stages of transformation, as well as to the maintenance of the
transformed cell phenotype (Howie et al., 2009; Klingelhutz and
Roman, 2012; McLaughlin-Drubin and Munger, 2009). E6 and E7
add to the carcinogenic process through their ability to interact with
and inactivate the function of cellular tumor-suppressor proteins,
and to modulate transcription and signaling activity of growth-
regulatory proteins. Many of the E6 functions that affect the global
transcriptional program of cervical cancer cells involve an interac-
tion with the E3 ubiquitin ligase E6AP (Beaudenon and Huibregtse,
2008; Kelley et al., 2005). E6AP is “hijacked” by E6 to target several
tumor-suppressor proteins for ubiquitin-dependent degradation,
including p53, hDlg, MCM7, Bak and the transcriptional repressor
of the hTERT promoter, NFX1-91 (Howie et al., 2009). E6AP has also
been shown to stabilize HPV E6 without requiring its catalytic
function (Tomaic et al., 2009).
The canonical Wnt/β-catenin pathway regulates stem cell
pluripotency and cell-fate decisions during development (Komiya
and Habas, 2008; Nusse, 2005; van Amerongen and Nusse, 2009).
Dysregulation of this pathway with aberrant accumulation of
β-catenin has been linked with the development of several types
of cancer, most notably colorectal cancer (Clevers, 2006; Kikuchi,
2003; Morin et al., 1997). The canonical Wnt signaling pathway
activates target genes through stabilization of β-catenin in the
nucleus. In the absence of a Wnt signal, β-catenin levels are
regulated by a multiprotein complex called the “destruction
complex”. Within this complex, the tumor-suppressor protein axin
and adenomatous polyposis coli (APC) proteins form a scaffold
that assists in β-catenin phosphorylation by casein-kinase 1α
(CK1α) and glycogen synthase kinase 3β (GSK3β). Recognition of
the phosphorylated protein by the SCF-β-TrCP ubiquitin ligase
complex targets it for proteasomal degradation. Binding of Wnt
ligands to Frizzled and LRP5/6 (low-density lipoprotein receptor-
related protein) receptor complexes leads to inactivation of the
“destruction complex”, allowing for stabilization of β-catenin and
its translocation to the nucleus (Clevers, 2006; Kimelman and Xu,
2006; Komiya and Habas, 2008). In the nucleus, β-catenin func-
tions as a cofactor for transcription factors of the T-cell factor/
lymphoid enhancing factor (TCF/LEF) family. It binds to and
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converts the TCF proteins into potent transcriptional activators by
altering their association with corepressors and recruiting coacti-
vators and chromatin-remodeling factors, thus ensuring effective
activation of the Wnt target genes, including cyclin D1, MYC and
TCF-1, among others (Mosimann et al., 2009; Willert and Jones,
2006). Among the various molecules involved in this pathway,
alterations in the β-catenin, APC, and axin genes are frequently
found in some human cancers, leading to the stabilization and
accumulation of β-catenin, and increased TCF-mediated gene
expression (Clevers, 2006; Kikuchi, 2003).
The role of the Wnt pathway in the development of cervical
cancer has not yet been established, although several reports have
provided evidence of a possible link. Mutations in the β-catenin gene
are uncommon in cervical carcinoma (Pereira-Suarez et al., 2002;
Su et al., 2003), but abnormal expression or cellular distribution of
β-catenin has been reported (Pereira-Suarez et al., 2002; Rodriguez-
Sastre et al., 2005; Shinohara et al., 2001; Ueda et al., 2001; Uren
et al., 2005), and elevated expression of β-catenin has been asso-
ciated with tumor progression (Rodriguez-Sastre et al., 2005; Uren
et al., 2005). Microarray studies on the expression proﬁles of cervical
cancer tissues have identiﬁed alterations in the expression of positive
and negative regulators of the Wnt signaling pathway (Perez-
Plasencia et al., 2007). Experimental evidence indicates that HPV16
E6 augments Wnt signaling (Lichtig et al., 2010). Activation of Wnt
signaling by both HPV E6 and E7 has been demonstrated in HPV16-
positive oropharyngeal squamous carcinoma cells (Rampias et al.,
2010). In transgenic mouse models, β-catenin has been shown to
accelerate HPV16-mediated cervical carcinogenesis (Bulut et al.,
2011), and another study identiﬁed the ability of HPV16 E6 to
enhance the canonical Wnt signaling in skin epidermis (Bonilla-
Delgado et al., 2012).
We have previously demonstrated the oncoprotein E6's ability to
enhance Wnt/β-catenin/TCF-dependent transcription (Lichtig et al.,
2010). This activity was absolutely dependent on the expression of
E6AP. In the present study, we elucidated the role of E6AP in the
regulation of Wnt signaling. E6 protein had a reduced half-life in
cells in which Wnt signaling was activated. E6AP stabilized E6 in
Wnt-activated cells and increased E6's enhancement of Wnt signal-
ing, independent of its ubiquitin ligase catalytic activity. Most
importantly, this study revealed the ability of E6AP, independent of
E6, to stabilize β-catenin and stimulate Wnt/β-catenin/TCF signaling,
functions that increased in the presence of E6. β-catenin stabilization
and stimulation of β-catenin/TCF signaling required the catalytic
activity of E6AP, the kinase activity of GSK3β, and the phosphoryla-
tion of β-catenin by GSK3β. The overall results of this study suggest
two different ways by which E6AP may cooperate with E6
in potentiating Wnt signaling: stimulating the signal in nonstimu-
lated cells by stabilizing β-catenin, and enhancing the signal in
Wnt-activated cells, at least in part, by stabilizing E6. The results are
relevant for understanding the role of E6AP in HPV carcinogenesis.
Results
The ubiquitin ligase activity of E6AP is not required for enhancement
of Wnt/TCF/β-catenin transcription in conjunction with E6
HPV16 E6 has been shown to cooperate with E6AP in the
enhancement of Wnt/β-catenin/TCF transcription (Lichtig et al.,
2010). To test whether the ubiquitin ligase activity of E6AP is
required for this function, we examined the activities of the wild-
type E6AP and a mutant E6AP defective in its catalytic function
(C820A) (Wolyniec et al., 2013). TCF–luciferase reporter assays
were performed using the super TOPFLASH/FOPFLASH luciferase
reporters as previously described (Lichtig et al., 2010). HEK293T
cells were transfected with the luciferase reporter, β-galactosidase
(β-gal), and hemagglutinin-tagged E6 (E6–HA) alone or in combi-
nation with wild-type or mutant HA–E6AP. Consistent with our
previous results (Lichtig et al., 2010), E6 by itself did not stimulate
Wnt signaling; however, in cells in which Wnt signaling was
stimulated by transfection of Wnt3a and HFz1, E6 enhanced
transcription, to up to three-fold that with the vector alone
(Fig. 1). Dose-dependent superactivation of the Wnt signal was
observed upon cotransfection of E6AP with E6. Both wild-type and
mutant E6AP superactivated the signal induced by E6, to up to
six- or sevenfold that with vector alone (Fig. 1A). Similar effects
were detected in primary human keratinocytes and in HaCaT cells
(immortalized human epidermal keratinocytes) transduced with
Wnt3a/HFz1, E6–HA and wild-type or mutant E6AP, although the
enhancement observed with E6 alone (up to twofold) and in
combination with E6AP (up to threefold) was lower than that
detected in HEK293T cells (Fig. 1B and C). These results showed
that the catalytic activity of E6AP is dispensable for its ability to
cooperate with E6 in the enhancement of Wnt signaling.
Expression levels of E6 decline in Wnt-activated cells in a
proteasome-dependent manner
Previous observations have indicated that E6 augments Wnt
signaling in cells in which the Wnt signal has been induced by
Fig. 1. Enhancement of the Wnt signal by HPV16 E6 is independent of E6AP ubiquitin ligase activity. Wnt3a, HFz1, TOP/FOP luciferase reporter, β-gal or Renilla luciferase
reporter, E6–HA and the indicated amounts of wild-type or mutant E6AP were transfected into HEK293T (A), PHKs (B) and HaCaT cells (C). Luciferase reporter activity was
evaluated 48 h post-transfection. Data representing average and SD of fold activation from at least three experiments are shown. Asterisk denotes signiﬁcant difference from
vector cells (Pr0.05).
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treatment with Wnt-conditioned medium (CM), LiCl, or transfec-
tion of β-catenin (Lichtig et al., 2010). Interestingly, E6 protein
levels in HEK293T cells treated with Wnt-CM were signiﬁcantly
reduced as compared to cells treated with the control medium (L)
(Fig. 2A). Similarly, coexpression of a codon-optimized E6 tagged
with the Flag epitope (E6opt–Flag; Samorski et al., 2006) and
Wnt3a indicated a dose-dependent reduction in E6 levels with an
increase in transfected Wnt3a (Fig. 2B). In cells treated with the
proteasome inhibitor MG132, levels of E6 in Wnt3a-expressing
cells recovered, indicating that Wnt3a induced proteasomal degra-
dation of E6 (Fig. 2C). Coimmunoprecipitation experiments with
Wnt3a–HA and E6opt–Flag did not reveal any direct interaction
between the two proteins (Fig. 2D). A similar reduction in E6
expression levels was observed in cells in which Wnt signaling had
been activated by treatment with BIO (Sigma B1686), a GSK3α/β
inhibitor and a Wnt-mimetic reagent, or β-catenin coexpression
(Fig. 3, described below). These results suggested that E6 function
may be compromised in Wnt-activated cells due to its lower
expression.
Catalytically active and inactive E6AP proteins stabilize HPV16 E6 in
Wnt-activated cells
E6AP has been reported to stabilize E6, without requiring its
catalytic function (Tomaic et al., 2009). We examined whether the
level of E6AP and its stabilizing effect on E6 are affected by
activation of the Wnt signaling pathway. HEK293T cells were
transfected with E6–HA alone or in combination with wild-type
or mutant HA–E6AP. Wnt signaling was induced by treating the
cells with 10 mM BIO, cotransfection with Wnt3a and HFz1, or
transfection with β-catenin (Fig. 3A–C).
Western blot analyses indicated that in all types of Wnt-
activated cells, the levels of both E6 and E6AP were signiﬁcantly
reduced (Fig. 3A–C). The decreases in E6 and E6AP were stronger
in cells treated with BIO or cotransfected with Wnt3a and HFz1
(Fig. 3A and B) than in cells transfected with β-catenin (Fig. 3C).
Coexpression of E6AP and E6 resulted in a signiﬁcant increase in
E6 level in all types of Wnt-activated cells, with the wild-type
E6AP being more effective than its mutant counterpart, most likely
due to its higher expression levels (Fig. 3A–C). To further conﬁrm
that E6 elevation by E6AP is due to E6 stabilization, the effect of
wild-type and mutant HA–E6AP on E6–HA stability was assessed
in half-life-determination assays. HEK293T cells were transiently
transfected with E6- and E6AP-expressing plasmids, and the levels
of E6 remaining at different times after the addition of cyclohex-
imide (80 μg/ml) were determined by western blot analysis
(Fig. 4A and B). Wnt signaling was induced by cotransfection with
β-catenin (Fig. 4B). The results of these experiments indicated that
both the wild-type and mutant E6AP extend the half-life of E6 in
Wnt-activated and nonactivated cells, with the mutant E6AP
having a weaker effect, most likely due to its own accelerated
degradation rate, particularly in Wnt-activated cells (Fig. 4B). The
protective effect of both the wild-type and mutant E6AP on E6 was
proteasome-dependent, as indicated by transient coexpression
experiments carried out in the presence and absence of the
proteasome inhibitor MG132. Signiﬁcant elevation in the relative
levels of E6 was observed in the vector cells treated with MG132.
This elevation was observed in both Wnt/β-catenin-activated and
nonactivated cells (Fig. 4C and D). In cells expressing E6AP, no
elevation (unstimulated, Fig. 4C) or a smaller elevation (β-catenin-
stimulated, Fig. 4D) in E6 was observed, indicating that E6AP
protects E6, at least in part, from proteasomal degradation.
The stabilizing effect of E6AP was also evident in immuno-
ﬂuorescence experiments (Fig. S1). In HEK293T cells transiently
transfected with vectors expressing Wnt3–HA and GFP–E6, ﬂuor-
escence of the latter was mainly nuclear and that of the former
was cytoplasmic. Fluorescence intensity of GFP–E6 was signiﬁ-
cantly reduced in cells coexpressing Wnt3a–HA (Fig. S1A). A
similar effect was observed in cells expressing E6opt–Flag and
Wnt3a–HA (Fig. S1B). Coexpression of Myc-tagged E6AP increased
Fig. 2. Wnt3a reduces the levels of E6 protein dependent on activity of the proteasome. (A–C) Western blot analyses of E6 levels in HEK293T cells. (A) Cells were transfected
with HPV16 E6–HA and treated with L or Wnt3a-CM. Average and SD of E6 levels from three independent experiments are shown. Asterisk denotes signiﬁcant difference in
E6 levels between L- and Wnt3a-treated cells (Pr0.1). (B) Cells were cotransfected with Wnt3a–HA and E6opt–Flag. GFP was cotransfected as a transfection and loading
control. (C) Cells were cotransfected with 0.5 mg E6opt–Flag and 0.5 mg Wnt3a–HA or vector. GFP was cotransfected as a transfection and loading control. Cells were treated
with the proteasome inhibitor MG132 or DMSO for 5 h and analyzed by western blot. (D) Coimmunoprecipitation of E6 with Wnt3a. HEK293T cells were cotransfected with
Wnt3a–HA and E6opt–Flag. A positive control DNA, CRD-Frizzled-6-Flag, was cotransfected with Wnt3a–HA. Total cellular extract (1.5 mg) was immunoprecipitated with the
anti-HA antibody and analyzed by western blot using the anti-HA and anti-Flag antibodies. In panels B–D, representative blots from one out of two experiments with similar
results are shown.
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the intensity of E6 ﬂuorescence in the Wnt3a/E6opt–Flag-expres-
sing cells (Fig. S1B). Intensity of Myc–E6AP was low in the
presence of Wnt3a, both alone and together with E6 (Fig. S1B).
In additional coexpression experiments, we examined whether
E6AP and activation of Wnt signaling have any effect on the levels
of HPV E7, a second HPV oncoprotein (McLaughlin-Drubin and
Munger, 2009). Interestingly, coexpression of HPV16 E7 and E6AP
in nonstimulated HEK293T cells increased the levels of E7 (Fig. 5).
However, in Wnt-stimulated cells, E7 levels were markedly
reduced and E6AP expression had no protective effect, in contrast
to the stabilizing effect on E6 observed in both nonstimulated and
Wnt-stimulated cells (Fig. 5).
Catalytically active E6AP and E6 cooperate to increase the expression
levels of β-catenin
In a previous study (Lichtig et al., 2010), we showed that
E6 alone does not signiﬁcantly alter the expression levels of
β-catenin. To test whether E6AP affects β-catenin expression,
alone or in combination with E6, coexpression experiments were
carried out with plasmids expressing β-catenin, E6, and wild-type
or mutant HA–E6AP. Western blot analyses indicated that wild-
type E6AP elevates the levels of both total cell β-catenin and
its transcriptionally active (nonphosphorylated) form when
expressed alone, and more robustly when expressed together
with E6 (Fig. 6A). E6 alone had little effect on β-catenin levels,
consistent with our previous observation (Lichtig et al., 2010). The
mutant E6AP, impaired in its ubiquitin ligase activity, had little
effect on β-catenin levels when expressed alone or together with
E6, despite being expressed at detectable levels (Fig. 6A). The
elevation of β-catenin level had a functional consequence on Wnt
signaling. In experiments with the luciferase reporter gene, wild-
type E6AP expressed in nonstimulated HEK293T cells activated
Wnt/β-catenin/TCF transcription, unlike the mutant E6AP which
was impaired in this activity (Fig. 6B). Transfection with 0.5 mg
E6AP elevated the signal sevenfold compared to the vector alone.
Coexpression of E6 with E6AP intensiﬁed the signal induced
by E6AP, reaching up to 12-fold activation. In cells transfected
with GFP-tagged β-catenin, elevated levels of both exogenous
(GFP-tagged) and endogenous active β-catenin were detected in
Fig. 3. Stimulation of Wnt signaling reduces the levels of E6 and E6AP. HEK293T cells were transfected with E6–HA, wild-type or mutant HA–E6AP, as indicated. Wnt
signaling was induced by treatment with 10 mM BIO (A), cotransfection with 1 μg Wnt3a and 0.3 μg HFz1 (B), or cotransfection with 1 μg GFP–β-catenin (C). Data representing
average and SD of the levels of E6 and E6AP from three independent experiments are shown. Asterisk denotes signiﬁcant difference in E6 levels between cells transfected
with E6AP or vector in Wnt-stimulated and nonstimulated cells (Pr0.05).
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the presence of the wild-type HA–E6AP and E6 (Fig. 6C). Con-
versely, depletion of E6AP in RKO colorectal cells expressing an
inducible E6AP shRNA reduced the levels of endogenous wild-type
β-catenin, and this effect was most evident on its transcriptionally
active form (Fig. 6D). To test whether the increase in β-catenin
levels by E6AP and E6 depends on the ability of E6 to bind E6AP,
coexpression experiments using E6 mutants that were either
impaired (E6 L110Q) or functional (E6 F2V) in E6AP binding were
carried out (Fig. 6E). Western blot analyses of transfected HEK293T
cells indicated that E6 F2V and wild-type E6 are equally active in
elevating the exogenously expressed β-catenin, total and active
form, whereas the mutant E6 L110Q was impaired in this ability.
These results indicate the requirement for E6–E6AP binding for
enhancement of β-catenin levels.
The catalytically active E6AP in conjunction with E6 stabilizes
β-catenin dependent on proteasome activity
The ability of E6AP together with E6 to alter β-catenin stability
was further validated in half-life-determination assays. HEK293T
Fig. 4. E6AP stabilizes HPV16 E6 and protects it from proteasomal degradation. HEK293T cells were transfected with E6–HA (2 μg) alone or in combination with wild-type or
mutant HA–E6AP (2 μg), as indicated. For stimulation of Wnt signaling, cells were cotransfected with GFP–β-catenin (1 μg) (B, D, stimulated cells) or vector (A, C,
nonstimulated cells). (A, B) Stability assay. Cycloheximide (80 μg/ml) was added 48 h after transfection. Cells were harvested at the indicated time points and analyzed by
western blot. The graphs show average7SD of the remaining E6 protein (percent of time 0) after cycloheximide addition. Data are from three independent experiments.
Signiﬁcant differences between E6AP wt/mut and vector were detected at 3 h and 9 h (A) or 3–9 h (B) (Pr0.05). (C, D) Proteasome inhibition. At 48 h after transfection,
MG132 (30 μM) or DMSO were added to the medium for 5 h. Western blot from one out of two independent experiments with similar results is shown.
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cells were transfected with GFP–β-catenin alone or together
with E6, and wild-type or mutant E6AP. The degradation rate of
β-catenin following the addition of cycloheximide (80 μg/ml) was
determined (Fig. 7). Initial levels of β-catenin were signiﬁcantly
higher in cells expressing E6 and wild-type E6AP, and the rate of
β-catenin decline was slowed signiﬁcantly. The level of β-catenin
in the presence of the mutant E6AP decreased rapidly, comparable
to or even faster than with the vector, although the same amounts
of mutant E6AP were still effective at stabilizing E6 protein (Fig. 7).
To evaluate whether E6 together with E6AP protects β-catenin
from proteasomal degradation, levels of β-catenin protein were
determined in HEK293T cells transfected with β-catenin, E6 and/or
E6AP, after treatment with 30 μM MG132. Western blot analyses
indicated an increase in the levels of total and active β-catenin in
vector cells treated with MG132 as compared to cells treated with
DMSO. In cells transfected with E6AP alone, and more robustly
together with E6, no signiﬁcant elevation was observed upon
MG132 treatment, indicating that wild-type E6AP and E6 protect
β-catenin from proteasomal degradation (Fig. 8A). E6 alone only
slightly restored β-catenin levels and the mutant E6AP did not
restore β-catenin levels at all (Fig. 8A). The same effect of MG132
was observed on the separated nuclear β-catenin, suggesting that
E6 in conjunction with E6AP protects the total cell and nuclear
pool of β-catenin from proteasomal degradation (Fig. 8B).
E6 and E6AP enhance translocation and accumulation of β-catenin in
the nucleus
We next examined whether E6 alone and in conjunction with
E6AP affects the cellular distribution of β-catenin. The effect of
E6/E6AP was initially tested on ectopically expressed β-catenin in
immunoﬂuorescence experiments using Myc- or GFP-tagged wild-
type β-catenin, and E6 and E6AP tagged with different epitopes
(Fig. 9A and S2). Expression of the Myc–β-catenin protein in
HEK293T cells was detected in the cell membrane and cytoplasm
(Fig. 9A), GFP–E6 was detected in the nucleus, and HA–E6AP was
mainly cytoplasmic. In cells coexpressing E6 and Myc–β-catenin,
β-catenin staining was mainly detected in the nucleus at increased
intensity. A similar effect was observed in cells expressing E6AP.
The effect was further intensiﬁed in cells expressing both E6 and
E6AP, where high staining intensity of nuclear β-catenin was
observed. The effects of E6 and E6AP were also evident on the
endogenous β-catenin (Fig. 9B), where they induced its nuclear
translocation and accumulation. Ectopic expression of GFP–β-
catenin revealed its ﬂuorescence mainly in the nucleus (Fig. S2).
The staining was diffuse or in ﬁne aggregates. Coexpression with
E6 or E6AP induced the accumulation of rough β-catenin aggre-
gates in the nucleus and the effect was further intensiﬁed by
coexpression with both E6 and E6AP, where a large proportion of
the cells contained rough aggregates of nuclear β-catenin. These
results suggested that E6 cooperates with E6AP in enhancing the
nuclear translocation and accumulation of β-catenin.
Ability of E6/E6AP to stabilize β-catenin and induce its nuclear
translocation depends on GSK3β activity and its phosphorylation of
β-catenin
In all of the experiments described above, the stabilizing effect
of E6 and E6AP on β-catenin was tested on wild-type β-catenin,
which is sensitive to GSK3β phosphorylation and subsequent
β-TrCP/SKP proteasomal degradation. We further examined the
effect of E6/E6AP on a mutant β-catenin (S33Y) which is refractory
to GSK3β-mediated phosphorylation. In the coexpression experi-
ments carried out using HEK293T cells and a Myc-tagged wild-
type or mutant β-catenin, expression of E6/E6AP elevated the
levels of the wild type but not the mutant β-catenin (Fig. 10A).
Accordingly, E6 and E6AP did not elevate the endogenous wild-
type β-catenin in cells transfected with Wnt3a/HFz1, where the
“destruction complex”was disrupted (Fig. 10B), or in cells in which
GSK3β was inhibited with LiCl or BIO (Fig. 10C). Similarly, in
HCT116 and SW480 colorectal carcinoma cells expressing mutant
β-catenin or mutant APC, respectively (Morin et al., 1997;
Munemitsu et al., 1995), no increase (Fig. S3A, HCT116), and even
a decrease (Fig. S3B, SW480) in the intensity of endogenous
β-catenin immunostaining was observed in the presence of E6,
E6AP or both. However, E6/E6AP was able to stabilize and induce
the nuclear accumulation of an ectopically expressed wild-type
β-catenin transfected into HCT116 cells (Fig. 11). Immunoﬂuores-
cence experiments with the transfected cells showed the accu-
mulation of aggregates of the ectopically expressed GFP–β-catenin
in the nucleus, and the effect was intensiﬁed by coexpression of E6
with E6AP, where rough aggregates of nuclear GFP–β-catenin were
observed (Fig. 11A). Western blot analysis indicated that E6 and
E6AP, individually, and more robustly when expressed together,
increased the levels of the active exogenous GFP–β-catenin, but
not those of the endogenous mutant β-catenin (Fig. 11B). These
results suggested that β-catenin stabilization by E6/E6AP and
subsequent nuclear accumulation depends on the activity of
GSK3β and its ability to phosphorylate β-catenin.
Discussion
The HPV oncoproteins E6 and E7 contribute directly to cell
transformation by activating different oncogenic signaling path-
ways (Klingelhutz and Roman, 2012). Our previous study showed
Fig. 5. Effect of Wnt stimulation and E6AP expression on protein levels of HPV16 E7. HEK293T cells were transfected with 2 μg E6–HA or HA–E7 and 2 μg wild-type or
mutant HA–E6AP, as indicated. Wnt signaling was simulated by cotransfection of 2 μg Wnt3a and 0.3 μg HFz1. At 48 h post-transfection, cells were lysed and subjected to
western blot analysis. Average and SD of the levels of E6 and E7 are shown. Data are from three independent experiments. Asterisk denotes signiﬁcant difference in E6 levels
between cells cotransfected with E6AP or vector in Wnt-stimulated and nonstimulated cells (Pr0.05). The increases in E7 level conferred by E6AP were not statistically
signiﬁcant (PZ0.1).
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the ability of E6 to enhance Wnt/β-catenin/TCF transcriptional
activity in an E6AP-dependent manner. Here we addressed the
role of E6AP in the Wnt signaling pathway, and identiﬁed its
ability to cooperate with E6 for two separate functions: enhance-
ment and stimulation of Wnt/β-catenin transcription. These func-
tions seem to be mediated through different mechanisms.
We showed that activation of Wnt signaling in HEK293T cells
by expression of Wnt3a, inhibition of GSK3β, or ectopic expression
of β-catenin, signiﬁcantly reduces E6 stability and expression
levels. In agreement with a previous report (Tomaic et al., 2009),
coexpression with E6AP in Wnt-activated cells signiﬁcantly stabi-
lized E6 levels by protecting it from proteasomal degradation. This
activity correlated with the enhancement in β-catenin/TCF tran-
scription. The ubiquitin ligase involved in the accelerated turnover
of E6 in Wnt-activated cells was not identiﬁed, but it does not
seem to be E6AP, because E6AP stabilized E6 independent of its
ubiquitin ligase activity. The protective effect of the mutant E6AP
was weaker, most likely due to its lower stability, particularly in
the Wnt-activated cells. The necessity for E6AP–E6 binding for E6
stabilization in Wnt-activated cells suggests that E6AP masks E6
Fig. 6. Expression of E6AP alone and together with E6 induces elevation in the levels and activity of β-catenin. (A, C) HEK293T cells were transfected with 1 μg Myc–β-catenin
(A), or GFP–β-catenin (C), and 2 μg of the indicated E6 and E6AP plasmids. At 48 h post-transfection, cells were lysed and subjected to western blot analysis. (B) HEK293T cells
were transfected with the TOP/FOP luciferase reporter (1 μg), β-gal (0.1 μg), 0.5 μg HA–E6AP and/or 0.5 μg E6–HA, as indicated. Luciferase activity was determined 48 h after
transfection. (D) RKO cells expressing an inducible E6AP shRNA were either treated or mock-treated with doxycycline. Cells were lysed 6 days after doxycycline addition and
subjected to western blot analysis. (E) HEK293T cells were transfected with the indicated E6 proteins (2 μg), 1 μg Myc–β-catenin and 2 μg wild-type HA–E6AP. At 48 h post-
transfection, cells were lysed and subjected to western blot analysis. Values of protein levels or luciferase activity in cells transfected with the indicated plasmids, relative to
vector (set at 1), are presented as average and SD of at least three experiments. Asterisk denotes signiﬁcant difference at Pr0.05.
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ubiquitylation sites or alters E6's structure by acting as a molecular
chaperone; such a notion has been previously proposed to explain
the stabilizing effect of E6AP in cells without activated Wnt
signaling (Tomaic et al., 2009). Alternatively, E6AP could protect
E6 from proteasomal degradation through its direct interaction
with the proteasome or with other ubiquitin ligases that interact
with the proteasome, including the UbA/UBL adaptor protein
HhR23a (Martinez-Noel et al., 2012 and references therein). The
stabilizing effect of E6AP was not, however, associated with
alteration in the nuclear targeting of E6.
Our results also showed that protein levels of E6AP are lower
in Wnt-activated cells. This suggests the existence of a negative-
feedback loop in which Wnt activation regulates the levels of
both E6 and E6AP. Interestingly, this study revealed E6AP's ability
to elevate E7 protein level in unstimulated cells, although its
stabilizing effect on E7 was less evident in Wnt-activated cells.
This is in accordance with our previous observation of E7's
inability to increase Wnt signaling in Wnt-activated cells
(Lichtig et al., 2010).
The mechanism by which E6, in conjunction with E6AP,
enhances Wnt-induced β-catenin/TCF transcriptional activity
needs to be further investigated. However, this activity appears
to be independent of the “degradation complex” (Lichtig et al.,
2010) and β-catenin stabilization, since E6/E6AP did not alter
β-catenin level in Wnt-stimulated cells. This activity also seems to
be independent of E6AP's ubiquitin ligase activity. The observed
correlation between E6 stabilization and enhancement of
β-catenin/TCF transcription suggests that E6AP's augmentation of
Wnt signaling may be mediated, at least in part, through stabiliza-
tion of E6 (Fig. S4).
Our results show, for the ﬁrst time, that E6AP alone may have a
regulatory function in the Wnt signaling pathway. E6AP over-
expression in nonstimulated cells stabilized β-catenin and acti-
vated Wnt/TCF transcription, whereas depletion of E6AP by means
of E6AP shRNA reduced β-catenin levels. E6 cooperated with E6AP
in the stabilization of β-catenin, potentiating this effect, and this
activity was dependent on the association between E6 and E6AP.
Additional results from immunoﬂuorescence experiments indi-
cated that E6 cooperates with E6AP in facilitating the nuclear
translocation and accumulation of β-catenin. The functional con-
sequence of β-catenin stabilization and nuclear accumulation was
reﬂected in the activation of Wnt/β-catenin/TCF transcription in
nonstimulated cells.
Taken together, the results of this study suggest that E6/E6AP
may act through different mechanisms to stimulate and augment
Wnt signaling (Fig. S4). Unlike the Wnt-signaling-augmentation
function of E6/E6AP, the Wnt-stimulatory function was dependent
on the ubiquitin ligase activity of E6AP and required the activity of
the kinase GSK3β. E6AP failed to elevate, and further stabilize,
β-catenin which was refractory to GSK3β phosphorylation, or
β-catenin expressed in cells with stimulated Wnt signaling or
inhibited GSK3β. This suggests that E6AP's ability to stabilize
β-catenin depends on the activity of the β-catenin “degradation
complex” and thus may not operate in cells with stimulated Wnt
signaling. E6AP may have a biological role in sustaining a basal
level of transcription from Wnt/TCF/β-catenin target genes in cells
in which Wnt signaling is “turned off” and the “degradation
complex” is active. This basal level might be needed to support
the low level of cell proliferation and survival previously shown to
be associated with activation of Wnt signaling (Barker and Clevers,
2006).
The mechanism by which E6AP alone, and together with E6,
stabilizes β-catenin needs to be further investigated. However, our
study showed that the ubiquitin ligase activity of E6AP is neces-
sary for stabilization of β-catenin. Wnt signaling is tightly regu-
lated by ubiquitylation (Tauriello and Maurice, 2010). Multiple E3
ligases target β-catenin for ubiquitin-mediated degradation. The
central ubiquitylation of β-catenin is by β-TrCP, which recognizes
CK1α/GSK3β-phosphorylated β-catenin, induces its ubiquitylation,
and subsequently targets it for degradation in the proteasome.
Additional ubiquitylation of β-catenin includes polyubiquitination
by Siah1 induced by genotoxic stress, which is independent of
β-catenin phosphorylation, and ubiquitylation by Jade-1, which is
phosphorylation-dependent (Tauriello and Maurice, 2010). Stabi-
lization of β-catenin through nonproteolytic ubiquitylation has
also been reported. The HECT-domain protein ligase EDD was
shown to ubiquitinate β-catenin through lysine 29- and 11-linked
ubiquitin chains leading to upregulation of β-catenin levels
(Hay-Koren et al., 2011). Interestingly, EDD was also shown to
interact with E6AP and E6, independently, and downregulate E6AP
expression (Tomaic et al., 2011). Experiments to determine
whether E6AP interacts with β-catenin and induces stabilizing
ubiquitylation of β-catenin are currently being carried out.
The relevance of the E6/E6AP-mediated stimulation and aug-
mentation of the Wnt pathway for HPV-mediated carcinogenicity
warrants further investigation, using squamous epithelial cells,
the target cells for HPV infection. E6AP has been shown to be
absolutely required for HPV E6 to cause cervical cancer in
transgenic mice (Shai et al., 2010). Whether E6AP enhances the
carcinogenicity of E6 in association with Wnt/β-catenin activation
Fig. 7. The half-life of β-catenin is elongated in cells expressing wild-type (wt) E6AP and E6. HEK293T cells were transfected with GFP–β-catenin (1 μg) alone, or together
with the indicated E6–HA (2 μg) and E6AP plasmids (2 μg). Cycloheximide (80 μg/ml) was added 48 h post-transfection. Cells were lysed at the indicated time points and
subjected to western blot analysis. Average and SD of the remaining active β-catenin at the indicated time points is shown. Data are from three independent experiments.
The difference between cells transfected with E6/E6APwt and vector is statistically signiﬁcant at 3–12 h (Pr0.05).
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has yet to be determined. However, in transgenic mouse models,
the rate of development of invasive cancer induced by HPV16 E7
has been shown to be accelerated by expression of a constitutively
active β-catenin (Bulut et al., 2011). In accordance with the results
herein, E6 was shown to enhance the nuclear accumulation of
β-catenin and signaling in transgenic mice (Bonilla-Delgado et al.,
2012). Additional studies are needed to test the role of E6AP and
E6 in Wnt/β-catenin-induced carcinogenicity.
Fig. 8. E6 and wild-type E6AP protect β-catenin from proteasomal degradation. HEK293T cells were transfected with Myc–β-catenin and the indicated plasmids. At 48 h
post-transfection, cells were treated with DMSO (control treatment) or 30 mM MG132 for 5 h. (A) Representative immunoblot of the total cell extract. (B) Representative
immunoblot of the nuclear fraction. The bars show average and SD of the total and active β-catenin from 3–5 experiments. Protein levels in the transfected E6 and/or E6AP
cells are relative to vector cells (set at 1). Asterisk denotes signiﬁcant difference from the vector (Pr0.05).
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Material and methods
Plasmids
PCEV29/HFz1 and Wnt3a–HA cloned into the pLNCX vector
were as described previously (Gazit et al., 1999). Cloning of the
Myc-tagged β-catenin and Myc-tagged constitutively active S33Y
mutant β-catenin (pCCB/Myc–β-catenin S33Y) was described pre-
viously (Golan et al., 2004). The Wnt-responsive TCF-dependent
luciferase construct, superTOPFLASH and its mutated version super-
FOPFLASH (also named Super8xTOPFlash and Super8xFOPﬂash,
respectively) were described previously (Lichtig et al., 2010).
The plasmids pCMV-Renilla (Promega) and pCMV/β-galactosidase
(β-gal; Clontech) were used to evaluate the efﬁciency of transfec-
tion. The HPV16 GFP–E6 (cloned into the pEGFP–C3) vector was as
described previously (Lichtig et al., 2010). The expression plasmid
encoding the HPV16 E6–HA cloned into the pJS55 vector was as
described previously (Lichtig et al., 2006). pTHampE6opt, which
contains the Flag-tagged, codon-optimized E6 sequence (Samorski
et al., 2006), was kindly provided by Dr. L. Gissmann, DKFZ,
Germany. The pcDNA3-HA–E6AP vector was kindly provided by
Dr. M. Scheffner (Department of Biology, University of Konstanz,
Fig. 9. β-catenin localization and levels in E6/E6AP-expressing cells. (A) HEK293T cells were transfected with plasmids encoding Myc–β-catenin (0.5 mg) alone or together
with GFP–E6 (0.5 mg) and/or wild-type HA–E6AP (0.5 mg), as indicated. (B) HEK293T cells were transfected with E6–HA (0.5 mg) and/or Myc–E6AP (0.5 mg). At 48 h post-
transfection, cells were subjected to immunoﬂuorescence analysis with the appropriate anti-tag antibodies. The cells were also stained with DAPI to visualize the nuclei. Cells
were observed under a confocal microscope. Fluorescence intensity of the samples was analyzed with LSM Dummy and measured per number of cells in the area. Average
and SD of the ﬂuorescence intensity of β-catenin are shown. Data for each sample are from ﬁve areas containing approximately 20 transfected cells. Asterisk denotes
signiﬁcant difference from the vector (Pr0.05).
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Germany). The E6AP mutant plasmid contains the HA-tagged E6AP
mutant C820A cloned into the pCMV4 vector (Wolyniec et al.,
2013). The GFP–β-catenin plasmid contains the human wild-type
β-catenin coding region inserted into the pEGFP-C2 (Clontech)
vector. The plasmid pcDNA3 HA 16E7 (Pim et al., 2005) was kindly
provided by Dr. D. Pim (International Centre for Genetic Engineer-
ing and Biotechnology, Trieste, Italy). The HPV16 E6 mutants L110Q
and F2V, cloned into the LXSN vector, were as described previously
(Sekaric et al., 2008). These mutant E6 genes were recloned into
the pJS-55 vector (Lichtig et al., 2010). HFz6-CRD was cloned into
pcDNA3 downstream of and in-frame with the Flag epitope (Golan
et al., 2004).
Cell cultures and transfections
Human embryonic kidney (HEK293T) cells, colon carcinoma
cell lines HCT116, RKO, and SW480, and immortalized epidermal
keratinocytes HaCaT, were cultured in DMEM supplemented with
10% fetal calf serum. Primary human keratinocytes obtained from
neonatal foreskin explants were grown in keratinocyte serum-free
Fig. 10. β-catenin stabilization by E6/E6AP depends on the activity of GSK3β. HEK293T cells were transfected with E6–HA (2 mg) and wild-type or mutant HA–E6AP (2 mg), as
indicated. The cells were also cotransfected with 1 mg of the wild-type or mutant Myc–β-catenin (S33Y) (A), 1 μg Wnt3a and 0.3 μg HFz1 (B), or treated with the GSK3β
inhibitors LiCl (30 mM) or BIO (10 mM) (C). At 48 h post-transfection, cells were lysed and subjected to western blot analysis. Representative western blots of one out of three
(A, B) or two (C) independent experiments are shown. Levels of the exogenous (A) and endogenous (B, C) β-catenin are shown. In A and B, asterisk denotes signiﬁcant
difference from the vector (Pr0.05).
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medium (KSFM) supplemented with 5 ng/ml epidermal growth
factor and 50 μg/ml bovine pituitary extract (Invitrogen). Cells
were transfected by a modiﬁed calcium phosphate procedure as
described previously (Sherman and Schlegel, 1996). Primary
human keratinocytes were transfected using the jetPEI reagent
(polyPlus Transfection), HaCaT cells were transfected with the K2
transfection system (Biontex). RKO cells containing inducible E6AP
shRNA (Wolyniec et al., 2013) were treated with 0.2 μg/ml dox-
ycycline (Sigma, D3072) for 6 days before protein-content analysis.
All cells described above contained E6AP.
Luciferase reporter activity assay
Cells growing in six-well dishes were transfected with DNA of
the superTOPFLASH or control superFOPFLASH (containing mutated
TCF/β-catenin binding sites; 1 μg) plasmid, β-gal (0.1 μg) or Renilla
luciferase (0.1 μg) (used to evaluate the transfection efﬁciency in
HEK293T and human keratinocytes, respectively), E6–HA (0.5 μg)
and wild-type or mutant E6AP plasmids (as indicated). Wnt
signaling was induced by cotransfection of the plasmids encoding
the Wnt ligand, pWnt3a–HA (0.1 μg), and the Wnt receptor human
Frizzled 1 (pHFz1; 0.3 μg). At 48 h after transfection, luciferase
levels were measured using the Luciferase Assay System kit
(Promega). Fireﬂy luciferase activity was normalized to the β-gal
or Renilla luciferase activity as described previously (Lichtig et al.,
2010). Data are presented as relative luciferase readouts (fold
activation) of E6/E6AP- vs. vector-expressing cells, where luciferase
readouts in the vector cells were set at 1.
Cellular fractionation
Nuclear fractions were prepared as described previously
(Dignam et al., 1983). HEK293T cells were washed in ice-cold
phosphate-buffered saline (PBS) and resuspended in cold buffer
Fig. 11. E6 and E6AP elevate the protein levels of wild-type β-catenin transfected into HCT116 cells. HCT116 cells were transiently transfected with GFP–β-catenin alone
(A, 0.5 μg, B, 1 μg) or together with the indicated E6 and E6AP plasmids (A, 0.5 μg, B, 2 μg). At 48 h post-transfection, cells were subjected to immunoﬂuorescence analysis
with the appropriate anti-tag antibodies (A) or lysed and subjected to western blot analysis (B). Immunoﬂuorescence images from one out of two experiments are shown in
A. Average and SD of the endogenous and exogenous active β-catenin is shown in B. The data are from three independent experiments. Asterisk denotes signiﬁcant difference
from the vector (Pr0.05).
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containing 10 mM HEPES, pH 7.9, 10 mM KCl, 1 mM dithiothreitol,
0.1 mM EGTA, 0.1 mM EDTA and protease inhibitor cocktail
(Sigma). Resuspended cells were lysed in 0.5% Nonidet P-40 for
15 min followed by centrifugation at 1000g for 5 min. Following
separation of the cytoplasmic fraction, the nuclei were harvested
by resuspension in ice-cold buffer (20 mM HEPES, pH 7.9, 0.4 mM
NaCl, 1 mM dithiothreitol, 1 mM EDTA, 1 mM EGTA and protease
inhibitor cocktail) followed by centrifugation at 13,000 rpm for
15 min at 4 1C.
Immunoprecipitation and western blot analysis
Total cell lysates were prepared using luciferase lysis buffer
(Promega) or RIPA buffer as described previously (Sherman and
Schlegel, 1996). Immunoprecipitation, electrophoresis on polya-
crylamide gels, transfer to nitrocellulose membranes and reaction
with antibodies were carried out as described previously (Lichtig
et al., 2006; Magal et al., 2005). Membranes were cut into strips,
blocked in 5% low-fat milk and then incubated with the speciﬁc
primary antibodies at 4 oC overnight. After washing in Tween/PBS,
the secondary antibody conjugated to horseradish peroxidase was
added for 1 h at room temperature. Membranes were washed
with PBS/0.1% Tween-20 and protein bands were visualized by
enhanced chemiluminescence detection using the EZ-ECL kit
(Biological Industries). Primary antibodies were: anti-β-catenin
(mouse, 610153) and anti-E6AP (mouse, 611416) from BD; anti-
actin (mouse, AC-15, A5441) and anti-Flag (rabbit, F7425) from
Sigma; anti-HA (rat, 12075900) from Roche; anti-tubulin (mouse,
B-7, sc-5286), anti-β-catenin (rabbit polyclonal, H-102, sc-7199),
anti-histone H1 (rabbit polyclonal, FL-219, sc-10806) and anti-GFP
(mouse, B-2, sc-9996) from Santa Cruz; anti-active-β-catenin
(anti-ABC) clone 8E7 (mouse, 05-665) from Millipore; anti-myc
(mouse monoclonal, 9B11) from Cell Signaling Technology. Sec-
ondary antibodies were: anti-mouse, anti-rat and anti-rabbit
conjugated to horseradish peroxidase from Jackson Immuno
Research Laboratories.
Immunoﬂuorescence staining
Cells grown on glass coverslips in 24-well plates were trans-
fected with the different plasmids, as indicated. At 48 h after
transfection, cells were washed with PBS and ﬁxed with 4%
paraformaldehyde for 20 min. After washing with PBS, cells were
permeabilized with 0.1% Triton X-100 for 10 min and incubated in
1% BSA solution for 1 h. Cells were stained with primary antibody
(described above for western blots) for 2 h followed by 1 h
staining with secondary antibody. Primary antibodies anti-E6AP,
anti-HA, anti-β-catenin, anti-active-β-catenin and anti-Flag were
used at a dilution of 1:150. Secondary antibodies 488 goat anti-
mouse (A11001) and 647 goat anti-rat (A21247) were used at
1:500; Alexa Fluor- and Rhodamine Red-X-conjugated donkey
anti-rabbit (711-296-152), both from Jackson Immuno Research
Laboratories, were used at 1:150. Cells were also stained with DAPI
(0.004%, and visualized using a confocal microscopy system (Leica
SP5). Fluorescence intensity was analyzed with LSM Dummy
software (Zeiss) and measured per number of cells in the area of
interest.
Statistical analysis
Data on activity and protein levels in the various assays are
presented in the ﬁgures as average (mean) values7SD. P value
was calculated by Student's t-test. Signiﬁcance was accepted at
Pr0.05 or Pr0.1, as indicated.
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